Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.
We report two cases of transfusion-dependent thalassemia treated by deferoxamine during the first trimesters of two successful pregnancies. The absence of any sign(s) of toxicity or teratogenicity is remarkable; despite the data from animal models, it seems that deferoxamine in humans is rather harmless for the fetus at the usually recommended doses.